DC Chemicals Limited
China
Product Name: GW1929
Price: $950.0/100mg $1900.0/250mg $3800.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1217466-21-1

1217466-21-1 structure

Name: GW 1929 hydrochloride
Chemical Name: GW1929
CAS Number: 1217466-21-1
Molecular Formula: C₃₀H₃₀ClN₃O₄
Molecular Weight: 532.030
Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
Create Date: 2019-07-03 19:18:23
Modify Date: 2024-01-02 20:05:44
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential[1][2][3].

Name	GW1929
Synonyms	L-Tyrosine, N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-, hydrochloride (1:1) MFCD28359221 N-(2-Benzoylphenyl)-O-{2-[methyl(2-pyridinyl)amino]ethyl}-L-tyrosine hydrochloride (1:1)

Description	GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	hPPARγ:8.84 (pKi)
In Vitro	GW1929 hydrochloride is a potent PPAR-γ activator, with pKis of 8.84, < 5.5, and < 6.5 for human PPAR-γ, PPAR-α, and PPAR-δ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively[1]. GW1929 hydrochloride (10 μM) inhibits TBBPA-induced caspase-3 increase and TBBPA-stimulated LDH release in neocortical cell cultures[2].GW1929 hydrochloride shows significant reduction in the COX-2, iNOS, MMP-9, TNFα and IL-6 levels[3].
In Vivo	GW1929 hydrochloride (0.5, 1, 5 mg/kg, p.o.) highly decreases nonfasted plasma glucose levels in Zucker diabetic fatty (ZDF) rats after treatment for 14 days, and possesses antilipolytic efficacy[1]. GW1929 hydrochloride (1, 5 mg/kg, p.o.) increases glucose-stimulated insuline secretion of β-cell in ZDF rats[1].GW1929 hydrochloride (10 mg/kg body weight) results in amelioration of muscle loss in tumour-bearing mice experimental cachexia[4].
References	[1]. Brown KK, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24. [2]. Wojtowicz AK, et al. PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox Res. 2014 Apr;25(3):311-22. [3]. Kaundal RK, et al. Ameliorative effects of GW1929, a nonthiazolidinedione PPARγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. Curr Neurovasc Res. 2011 Aug 1;8(3):236-45. [4]. Moore-Carrasco R, et al. Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncol Rep. 2008 Jan;19(1):253-6.

Molecular Formula	C₃₀H₃₀ClN₃O₄
Molecular Weight	532.030
Exact Mass	531.192505
Appearance	GW1929
Storage condition	store at -20℃ for one year（Powder）

1217466-21-1	179246-08-3
880635-03-0	1510-05-0
405911-17-3	197890-44-1
635702-64-6	6823-69-4
2452-41-7	70952-50-0